Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Lusutrombopag Patent Expiration

Lusutrombopag is Used for managing thrombocytopenia in adult patients with chronic liver disease undergoing a procedure. It was first introduced by Vancocin Italia Srl in its drug Mulpleta on Jul 31, 2018.


Lusutrombopag Patents

Given below is the list of patents protecting Lusutrombopag, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Mulpleta US7601746 Compounds exhibiting thrombopoietin receptor agonism Sep 05, 2024 Vancocin Italia
Mulpleta US8530668 Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor Jan 21, 2030 Vancocin Italia
Mulpleta US8889722 Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor Jul 29, 2028 Vancocin Italia
Mulpleta US9427402 Preparation for improving solubility of poorly soluble drug Sep 29, 2031 Vancocin Italia


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳